• Skip to content
  • Skip to footer
Therachon

Therachon

  • About Us
    • Management Team
    • Board of Directors
    • Partners
  • Our Focus
    • Achondroplasia
    • Short Bowel Syndrome
    • Pipeline
  • News & Media
  • Contact Us

Achondroplasia

Our Focus Achondroplasia

We’re working to advance a first-in-class, best-in-disease therapy for patients facing unmet medical needs and no approved therapies. Our investigational TA-46 product candidate offers the potential to target the molecular alterations that are the root cause of achondroplasia.

Achondroplasia is an autosomal dominant disorder characterized by dwarfism and disproportionate shortness of limbs, accompanied by life-altering complications. Achondroplasia is caused by a gene alteration (mutation) in the FGFR3 gene.

Approximately 97% of achondroplasia cases are caused by a single mutation in the fibroblast growth factor receptor 3 (FGFR3), a G380R substitution which results in a ligand dependent gain of function. This leads FGFR3 to send persistent rather than transient growth inhibition signals, preventing its down-regulation. The ensuing disrupted endochondral ossification results in disproportionate shortness of limbs, and is associated with debilitating orthopedic, neurological and ENT (Ear Nose and Throat) complications.

This rare condition affects approximately 1 in 25,000 live births.

Children are typically diagnosed at birth, but increasingly parents are finding out via prenatal ultrasounds. Currently, the only available therapeutic option for achondroplasia is limb lengthening, an extremely invasive surgical procedure that addresses height but not other achondroplasia-associated complications.

Mechanism of Action for TA-46 in Achondroplasia

Normal bone growth

elimination of activated receptor

In Achondroplasia

activated receptor not eliminated always “on”

sFGFR3 decoy strategy

competition preventing ligand binding and membrane-bound receptor dimersation (receptor not turned “on”)

In Other Words...

Imagine you're driving a car and you want to go faster to keep up with traffic. However, for some reason the car won't accelerate. Something is pushing the brake pedal down, not allowing you to keep up with the other cars. Suddenly, something unlocks, the brake pedal is loosened, and the car is able to reach its cruising speed potential.

That is what we want to do, unlock the growth potential to restore normal bone growth and development.

More than 80% of children with drawfism have average height parents and siblings.

The most frequenly diagnosed cause of genetically determined short stature is achondroplasia, a genetic condition that results in disroportionately short arms and legs

The average height of an adult with dwarfism is 4’0/122 cm, but typical heights rangeform 2’8/8’2cm to 4’8/142cm

Publications

  • Celine Saint-Laurent, Stephanie Garcia, Vincent Sarrazy, Karine Dumas, Florence Authier, Sophie Sore, Albert Tran, Philippe Gual, Isabelle Gennero, Jean-Pierre Salles, Elvire Gouze (2018) Early postnatal soluble FGFR3 therapy prevents the atypical development of obesity in achondroplasia. Online PLOS ONE
  • Garcia, S., Dirat, B., Tognacci, T., Rochet, N., Mouska, X., Bonnafous, S., Patouraux, S., Tran, A., Gual, P., Le Marchand-Brustel, Y., Gennero, I., and Gouze, E. (2013) Postnatal Soluble FGFR3 Therapy Rescues Achondroplasia Symptoms and Restores Bone Growth in Mice. Science Translational Medicine 5, 203ra124
  • Rousseau, F., Bonaventure, J., Legeai-Mallet, L., Pelet, A., Rozet, J. M., Maroteaux, P., Le Merrer, M., and Munnich, A. (1994) Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 371, 252-254
  • Donaldson, J., Aftab, S., and Bradish, C. (2015) Achondroplasia and limb lengthening: Results in a UK cohort and review of the literature. J Orthop 12, 31-34
  • Ireland, P.J., Pacey, V., Zankl, A., Edwards, P., Johnston, L. M., and Savarirayan, R. (2014) Optimal management of complications associated with achondroplasia. Appl Clin Genet 7, 117-125
  • Unger, S., Bonafe, L., Gouze, E. (2017) Current care and investigational therapies in achondroplasia. Curr Osteoporosis Report 14, in press.

View Our Pipeline

Footer

  • About Us
  • Our Focus
  • Contact Us
  • News & Media
  • Join Us
Therachon logo

Terms of Use | Privacy Policy

Copyright © Therachon. 2019 All Rights Reserved.